Sponsors (8)
The bill trades substantial legal and economic relief and regulatory clarity for compliant consumers, businesses, and tribes against increased public‑health and enforcement risks plus new compliance costs and potential intergovernmental confusion.
People and businesses that follow the Act (compliant consumers, patients, and licensed operators) will no longer face federal criminal drug charges, civil forfeiture of property, or money‑laundering treatment for those activities, protecting assets and reducing prosecution risk.
State- and Tribe-permitted businesses gain major economic and commercial certainty: reduced criminal exposure, allowance for interstate transport between consenting jurisdictions, and eligibility for normal tax deductions/credits (IRC §280E relief), which lowers tax burdens and legal risk for market participants.
Federal rules will create safety and quality guards — testing, manufacturing standards, marketing/postmarket reporting, and an excise-tax-funded stream for enforcement, testing, youth prevention, and substance‑abuse education — improving product safety and supporting prevention efforts.
Removing federal scheduling and narrowing federal deterrents could increase diversion to non-permissive States, expand youth and younger‑adult access (including ages 18–20), and worsen marijuana-impaired driving risks, creating substantial public health and safety concerns.
New federal excise taxes, testing and manufacturing requirements, and bank/compliance adjustments could raise prices and operating costs for producers/retailers, potentially disadvantaging licensed businesses versus illicit operators and increasing consumer costs.
The Act creates potential for regulatory confusion and uneven enforcement across federal, state, and tribal systems (preemption disputes, a compliance 'cliff' for noncompliant actors, and reliance on varying state enforcement), increasing legal uncertainty for businesses, consumers, and law enforcement.
Based on analysis of 9 sections of legislative text.
Creates a federal framework exempting state/tribal‑compliant marijuana from most federal drug laws, directs FDA regulation of products, creates a federal excise tax, and shields compliant transactions from federal penalties.
Introduced April 17, 2025 by David Joyce · Last progress April 17, 2025
Creates a federal framework that treats marijuana produced, sold, and transported in compliance with state or federally recognized tribal law as exempt from most federal criminal drug provisions and certain federal tax and forfeiture rules. It directs federal agencies to regulate marijuana products, requires a federal excise tax to fund regulation and prevention, and protects compliant interstate commerce between jurisdictions that permit cannabis activity. The bill directs the Attorney General and FDA to issue rules quickly (within 180 days) to implement the new status, requires a GAO study on traffic safety effects within one year, and affirms support for tribal self-determination in FDA matters related to marijuana. It also removes several federal criminal penalties and tax barriers for persons and businesses operating in compliance with state or tribal marijuana laws.